Simulations Plus

Software Programs Will Help Prioritize Testing for the National Toxicology Program

Preliminary Revenues Increased 11.7% for New Record Third Quarter

Software Upgrade Increases Number of Predictive Models, Adds User Convenience Features

US FDA, UK MHRA, and European EMA Accept Simulation Results in Applications

Company declares increased cash dividend of $0.03 per share

Second quarter net sales increase 11.8%; net income up 26.5%

Conference Call to be on Wednesday, April 10, at 4:30 PM ET

Revenues Increase 11.7% for New Record Quarter

Net sales increase 1.9% to first-quarter record $2.290 million; Earnings per share $0.04

Company declares accelerated cash dividend of $0.14 per share

Revenues Increase 1.9% for New Record 1st Quarter

Fiscal Year Pharmaceutical Software and Services Up 8.1%, EPS Up 11.1%

Conference Call to be on Monday, November 19, 2012, at 4:15 PM EST

Company declares cash dividend of $0.05 per share

Simulations Plus is the only non-European company invited to consortium

Pharmaceutical Software and Services Revenues Increase 14.9% for Record 4th Quarter, up 8.1% for the Record Fiscal Year

Company declares cash dividend of $0.05 per share